<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.1d3 20150301//EN"  "JATS-archivearticle1.dtd"><article article-type="research-article" dtd-version="1.1d3" xmlns:xlink="http://www.w3.org/1999/xlink"><front><journal-meta><journal-id journal-id-type="nlm-ta">elife</journal-id><journal-id journal-id-type="hwp">eLife</journal-id><journal-id journal-id-type="publisher-id">eLife</journal-id><journal-title-group><journal-title>eLife</journal-title></journal-title-group><issn publication-format="electronic">2050-084X</issn><publisher><publisher-name>eLife Sciences Publications, Ltd</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">13964</article-id><article-id pub-id-type="doi">10.7554/eLife.13964</article-id><article-categories><subj-group subj-group-type="display-channel"><subject>Short Report</subject></subj-group><subj-group subj-group-type="heading"><subject>Cancer Biology</subject></subj-group><subj-group subj-group-type="heading"><subject>Cell Biology</subject></subj-group></article-categories><title-group><article-title>ERG signaling in prostate cancer is driven through PRMT5-dependent methylation of the androgen receptor</article-title></title-group><contrib-group><contrib contrib-type="author" id="author-49661"><name><surname>Mounir</surname><given-names>Zineb</given-names></name><aff><institution>Genentech</institution>, <addr-line><named-content content-type="city">South San Francisco</named-content></addr-line>, <country>United States</country></aff><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-49662"><name><surname>Korn</surname><given-names>Joshua M</given-names></name><aff><institution content-type="dept">Department of Oncology</institution>, <institution>Novartis Institutes for BioMedical Research</institution>, <addr-line><named-content content-type="city">Cambridge</named-content></addr-line>, <country>United States</country></aff><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-49663"><name><surname>Westerling</surname><given-names>Thomas</given-names></name><aff><institution content-type="dept">Department of Medical Oncology, Center for Functional Cancer Epigenetics, Dana-Farber Cancer Institute</institution>, <institution>Harvard Medical School</institution>, <addr-line><named-content content-type="city">Boston</named-content></addr-line>, <country>United States</country></aff><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-49664"><name><surname>Lin</surname><given-names>Fallon</given-names></name><aff><institution content-type="dept">Department of Oncology</institution>, <institution>Novartis Institutes for BioMedical Research</institution>, <addr-line><named-content content-type="city">Cambridge</named-content></addr-line>, <country>United States</country></aff><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-49665"><name><surname>Kirby</surname><given-names>Christina A</given-names></name><aff><institution content-type="dept">Center for Proteomic Chemistry</institution>, <institution>Novartis Institutes for BioMedical Research</institution>, <addr-line><named-content content-type="city">Cambridge</named-content></addr-line>, <country>United States</country></aff><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-49666"><name><surname>Schirle</surname><given-names>Markus</given-names></name><aff><institution content-type="dept">Developmental and Molecular Pathways</institution>, <institution>Novartis Institutes for Biomedical Research</institution>, <addr-line><named-content content-type="city">Cambridge</named-content></addr-line>, <country>United States</country></aff><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-49667"><name><surname>McAllister</surname><given-names>Gregg</given-names></name><aff><institution content-type="dept">Developmental and Molecular Pathways</institution>, <institution>Novartis Institutes for Biomedical Research</institution>, <addr-line><named-content content-type="city">Cambridge</named-content></addr-line>, <country>United States</country></aff><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-49668"><name><surname>Hoffman</surname><given-names>Greg</given-names></name><aff><institution content-type="dept">Developmental and Molecular Pathways</institution>, <institution>Novartis Institutes for Biomedical Research</institution>, <addr-line><named-content content-type="city">Cambridge</named-content></addr-line>, <country>United States</country></aff><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-49669"><name><surname>Ramadan</surname><given-names>Nadire</given-names></name><aff><institution content-type="dept">Developmental and Molecular Pathways</institution>, <institution>Novartis Institutes for Biomedical Research</institution>, <addr-line><named-content content-type="city">Cambridge</named-content></addr-line>, <country>United States</country></aff><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-49670"><name><surname>Hartung</surname><given-names>Anke</given-names></name><aff><institution>Organovo</institution>, <addr-line><named-content content-type="city">San Diego</named-content></addr-line>, <country>United States</country></aff><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-49671"><name><surname>Feng</surname><given-names>Yan</given-names></name><aff><institution content-type="dept">Developmental and Molecular Pathways</institution>, <institution>Novartis Institutes for Biomedical Research</institution>, <addr-line><named-content content-type="city">Cambridge</named-content></addr-line>, <country>United States</country></aff><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-55324"><name><surname>Kipp</surname><given-names>David Randal</given-names></name><aff><institution content-type="dept">Oncology</institution>, <institution>NIBR</institution>, <addr-line><named-content content-type="city">Cambridge</named-content></addr-line>, <country>United States</country></aff><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-57377"><name><surname>Quinn</surname><given-names>Christopher</given-names></name><aff><institution content-type="dept">Oncology</institution>, <institution>NIBR</institution>, <addr-line><named-content content-type="city">Cambridge</named-content></addr-line>, <country>United States</country></aff><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-57378"><name><surname>Fodor</surname><given-names>Michelle</given-names></name><aff><institution content-type="dept">Oncology</institution>, <institution>NIBR</institution>, <addr-line><named-content content-type="city">Cambridge</named-content></addr-line>, <country>United States</country></aff><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-57379"><name><surname>Baird</surname><given-names>Jason</given-names></name><aff><institution content-type="dept">Oncology</institution>, <institution>NIBR</institution>, <addr-line><named-content content-type="city">Cambridge</named-content></addr-line>, <country>United States</country></aff><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-54509"><name><surname>Schoumacher</surname><given-names>Marie</given-names></name><aff><institution>Laboratoires Servier</institution>, <addr-line><named-content content-type="city">Neuilly-sur-Seine</named-content></addr-line>, <country>France</country></aff><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-49673"><name><surname>Meyer</surname><given-names>Ronald</given-names></name><aff><institution content-type="dept">Department of Oncology</institution>, <institution>Novartis Institutes for Biomedical Research</institution>, <addr-line><named-content content-type="city">Cambridge</named-content></addr-line>, <country>United States</country></aff><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-49674"><name><surname>Deeds</surname><given-names>James</given-names></name><aff><institution content-type="dept">Department of Oncology</institution>, <institution>Novartis Institutes for Biomedical Research</institution>, <addr-line><named-content content-type="city">Cambridge</named-content></addr-line>, <country>United States</country></aff><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-49682"><name><surname>Buchwalter</surname><given-names>Gilles</given-names></name><aff><institution>Celgene Avilomics Research</institution>, <addr-line><named-content content-type="city">Bedford</named-content></addr-line>, <country>United States</country></aff><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-49675"><name><surname>Stams</surname><given-names>Travis</given-names></name><aff><institution content-type="dept">Center for Proteomic Chemistry</institution>, <institution>Novartis Institutes for Biomedical Research</institution>, <addr-line><named-content content-type="city">Cambridge</named-content></addr-line>, <country>United States</country></aff><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-49676"><name><surname>Keen</surname><given-names>Nicholas</given-names></name><aff><institution content-type="dept">Department of Oncology</institution>, <institution>Novartis Institutes for Biomedical Research</institution>, <addr-line><named-content content-type="city">Cambridge</named-content></addr-line>, <country>United States</country></aff><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-15959"><name><surname>Sellers</surname><given-names>William R</given-names></name><aff><institution content-type="dept">Department of Oncology</institution>, <institution>Novartis Institutes for BioMedical Research</institution>, <addr-line><named-content content-type="city">Cambridge</named-content></addr-line>, <country>United States</country></aff><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-3615"><name><surname>Brown</surname><given-names>Myles</given-names></name><aff><institution content-type="dept">Department of Medical Oncology, Center for Functional Cancer Epigenetics, Dana-Farber Cancer Institute</institution>, <institution>Harvard Medical School</institution>, <addr-line><named-content content-type="city">Boston</named-content></addr-line>, <country>United States</country></aff><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" corresp="yes" id="author-48181"><name><surname>Pagliarini</surname><given-names>Raymond A</given-names></name><aff><institution>Celgene Avilomics Research</institution>, <addr-line><named-content content-type="city">Bedford</named-content></addr-line>, <country>United States</country><email>raymond.pagliarini@novartis.com</email></aff><xref ref-type="fn" rid="conf1"/></contrib></contrib-group><contrib-group content-type="section"><contrib contrib-type="editor" id="author-30083"><name><surname>Armstrong</surname><given-names>Scott A</given-names></name><role>Reviewing editor</role><aff><institution>Memorial Sloan Kettering Cancer Center</institution>, <country>United States</country></aff></contrib></contrib-group><pub-date date-type="pub" publication-format="electronic"><day>16</day><month>05</month><year>2016</year></pub-date><elocation-id>e13964</elocation-id><supplementary-material><ext-link xlink:href="elife-13964-supp-v1.zip">Download zip</ext-link><p>Any figures and tables for this article are included in the PDF. The zip folder contains additional supplemental files.</p></supplementary-material><history><date date-type="received"><day>21</day><month>12</month><year>2015</year></date><date date-type="accepted"><day>06</day><month>05</month><year>2016</year></date></history><permissions><copyright-statement>Â© 2016, Mounir et al</copyright-statement><copyright-year>2016</copyright-year><copyright-holder>Mounir et al</copyright-holder><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><license-p>This article is distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link> permitting unrestricted use and redistribution provided that the original author and source are credited.</license-p></license></permissions><abstract><p>The <italic>TMPRSS2:ERG</italic> gene fusion is common in androgen receptor (AR) positive prostate cancers, yet its function remains poorly understood. From a screen for functionally relevant ERG interactors, we identify the arginine methyltransferase PRMT5. ERG recruits PRMT5 to AR-target genes, where PRMT5 methylates AR on arginine 761. This attenuates AR recruitment and transcription of genes expressed in differentiated prostate epithelium. The AR-inhibitory function of PRMT5 is restricted to <italic>TMPRSS2:ERG</italic>-positive prostate cancer cells. Mutation of this methylation site on AR results in a transcriptionally hyperactive AR, suggesting that the proliferative effects of ERG and PRMT5 are mediated through attenuating AR's ability to induce genes normally involved in lineage differentiation. This provides a rationale for targeting PRMT5 in <italic>TMPRSS2:ERG</italic> positive prostate cancers. Moreover, methylation of AR at arginine 761 highlights a mechanism for how the ERG oncogene may coax AR towards inducing proliferation versus differentiation.</p></abstract><kwd-group kwd-group-type="research-organism"><title>Research organism</title><kwd>Human</kwd></kwd-group></article-meta></front><back><fn-group content-type="competing-interest"><title>Competing interest</title><fn fn-type="conflict" id="conf1"><p>The authors declare that no competing interests exist.</p></fn></fn-group></back></article>